SEB Asset Management AB Invests $109.73 Million in Edwards Lifesciences Corporation $EW

SEB Asset Management AB bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,370,202 shares of the medical research company’s stock, valued at approximately $109,726,000.

Several other hedge funds and other institutional investors have also bought and sold shares of EW. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth about $25,000. MV Capital Management Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $27,000. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $28,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $85.72 on Friday. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The firm has a market capitalization of $49.36 billion, a price-to-earnings ratio of 45.60, a PEG ratio of 2.15 and a beta of 0.86. The business has a 50-day simple moving average of $87.34 and a 200 day simple moving average of $83.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EW has been the subject of several recent analyst reports. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Citigroup increased their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Mizuho raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday. Evercore reiterated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, TD Cowen reiterated a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.95.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president owned 33,934 shares in the company, valued at approximately $2,816,861.34. The trade was a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 45,577 shares of company stock valued at $3,855,527 over the last ninety days. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.